The renin-angiotensin system (RAS) constitutes a key hormonal system in the physiological regulation of blood pressure via peripheral and central mechanisms. Dysregulation of the RAS is considered a major factor in the development of cardiovascular pathologies, and pharmacologic blockades of this system by the inhibition of angiotensin-converting enzyme (ACE) or antagonism of the angiotensin type 1 receptor (AT1R) are effective therapeutic regimens. The RAS is now defined as a system composed of different angiotensin peptides with diverse biological actions mediated by distinct receptor subtypes. The classic RAS comprises the ACE-Ang II-AT1R axis that promotes vasoconstriction, water intake, sodium retention and increased oxidative stress, fibrosis, cellular growth, and inflammation. The nonclassical or alternative RAS is composed primarily of the ACE2-Ang-(1-7)-AT7R pathway that opposes the Ang II-AT1R axis. In lieu of the complex aspects of this system, the current review assesses the enzymatic cascade of the alternative Ang-(1-7) axis of the RAS.
- dipeptidyl peptidase 3
The renin-angiotensin system (RAS) has been long defined as a circulating endocrine system composed of an enzymatic cascade that includes renin to initiate the RAS through the conversion of the large precursor protein angiotensinogen (>350 amino acids) to the inactive decapeptide Ang I and the subsequent generation of the bioactive octapeptide Ang II by angiotensin-converting enzyme (ACE) (Figure 1). Ang II binds to the angiotensin type 1 receptor (AT1R) to mediate both peripheral and central mechanisms in the regulation of blood pressure. Activation of the ACE-Ang II-AT1R pathway is also associated with various pathological responses including fibrosis, inflammation, metabolic dysregulation, heart failure, cancer, aging, and diabetic injury [1–5]. Indeed, the targeting of this pathway by biochemical approaches that block the formation of Ang II through ACE inhibitors or binding of Ang II to the AT1R by receptor antagonists is an effective therapy for the treatment of cardiovascular disease. It is now evident that these therapies have revealed alternative pathways within the RAS that may contribute to the beneficial actions of the RAS blockade. For example, the targeting of ACE reduces Ang II expression, but markedly enhances the circulating levels of Ang-(1-7), a ligand for the AT7/MasR that generally opposes the actions of the Ang II-AT1R pathway [6, 7]. The chronic treatment with AT1R antagonists may also increase the formation of Ang-(1-7) through ACE2, as well as shunt Ang II to the AT2R pathway that shares similar properties to the Ang-(1-7) system [8, 9]. Since the RAS is now viewed as a more complex array of components that can be functionally partitioned into distinct receptors and peptide ligands, we present an overview of the peptidases the may constitute the alternative Ang-(1-7) axis of the RAS. We include a discussion of renin, ACE, and chymase as they pertain to the formation of the substrates Ang I and Ang II for the direct processing to Ang-(1-7), as the well as the role of ACE to metabolize Ang-(1-7).
Renin [EC 22.214.171.124] belongs to the family of aspartyl-type acid proteases (molecular size: 30–40 kDa); however, the protease exhibits a more neutral pH optima of 6.5–8.0. The only known substrate for renin is angiotensinogen, and renin cleaves off the N-terminal portion of angiotensinogen to form the inactive peptide Ang I. The formation of Ang I is considered the enzymatic event that initiates the RAS cascade (Figure 1). The enzyme is synthesized predominantly in the juxtaglomerular (JG) cells of the kidney and is stored in both inactive (prorenin) and active forms for subsequent release into the afferent arteriole to reach the circulation. The collecting duct (CD) cells are another source of renin within the kidney that primarily secretes the active form of renin from the apical aspect of the principal cells into the tubular fluid [10, 11]. The distal secretion of renin into the tubular fluid would presumably contribute to the processing of angiotensinogen that may arise from either proximal tubule synthesis or apical release or the glomerular filtration of the protein. Interestingly, the regulation of JG renin appears to be distinct from CD renin as Ang II reduces JG renin release and synthesis constituting the classic short-loop negative feedback system for RAS activation, whereas the peptide stimulates CD renin release suggesting a positive feedback system for renin in the distal nephron [12, 13].
There is evidence for alternative gene products of renin expressed in the kidney, brain, heart, and adrenal gland [14–17]. These products arise from an alternative start site for renin transcription that is situated downstream from the typical start site and yields a shorter, but active form of the enzyme. The truncated form of renin lacks the secretory signal of the protein and the enzyme is not secreted, but resides within the cell. Peters and colleagues find that truncated renin specifically localized to the mitochondria and that the active form of renin, but not prorenin, was internalized by mitochondria [14, 18, 19]. The overexpression of the active renin isoform protected the cells under high glucose conditions and this effect was not reversed by the renin inhibitor aliskerin or an AT1R antagonist suggesting that the beneficial effects may not reflect activation of the Ang II-AT1R axis . In support of these findings, we recently reported the presence of active renin in isolated mitochondria from the sheep renal cortex . In this case, we also quantified the mitochondrial levels of both Ang II and Ang-(1-7) (50–60 fmol/mg protein), which may indicate that the intracellular form of renin contributes to the cellular expression of angiotensin peptides within the kidney . In the renal NRK-52 epithelial cell line, immunocytochemical staining for renin was evident in the nucleus of these cells . Renin activity as measured by aliskerin-sensitive inhibition of Ang I formation from angiotensinogen was also evident in isolated nuclei in the renal epithelial NRK-52 cells, as well as quantifiable levels of Ang I, Ang II, and Ang-(1-7) . In confirmation of intracellular renin within the kidney, Ishigami and colleagues report a truncated renin transcript expressed in the proximal tubules of the mouse kidney . Overexpression of the renin isoform within the proximal tubules was associated with a sustained elevation in blood pressure and no change in the circulating levels of renin . Although the intracellular distribution of the renin isoform was not ascertained, the fact that overexpression of tubular renin augmented blood pressure is consistent with previous studies demonstrating that the increased expression of proximal tubule angiotensinogen, the AT1R, or intracellular Ang II also resulted in a sustained increase in blood pressure [23–28].
3. Angiotensin-converting enzyme
The predominant pathway of the classical RAS for the conversion of Ang I to the bioactive peptide Ang II is catalyzed by the metallopeptidase ACE [EC 126.96.36.199], a dipeptidyl carboxypeptidase that cleaves two residues from the carboxy terminus of Ang I (Figure 1). The peptidase is a membrane-bound, glycosylated protein (120–180 kDa) ubiquitously expressed in multiple tissues . Soluble forms of the enzyme are present in the circulation, cerebrospinal fluid (CSF), lymph fluid, and urine that fully retain peptidase activity . The soluble form of ACE arises from the hydrolysis of the membrane-anchoring or stalk region of the protein that may reflect the processing by A Disintegrin and Metalloproteinase (ADAM) family of metalloenzymes, although the precise role of ACE shedding in cardiovascular disease is presently unclear. Somatic ACE is characterized by two active sites termed N and C terminal domains that likely arose from the gene duplication of germinal or testicular ACE that contains only the single C terminal-active site. Importantly, in addition to forming Ang II, ACE degrades a number of other peptides that exhibit cardiovascular actions including bradykinin, substance P, acetyl-SDKP, and Ang-(1-7) . Indeed, the cardioprotective effects of ACE inhibitors may reflect the protection of these peptides from metabolism in addition to the blockade of Ang II formation. We showed that ACE hydrolyzes Ang-(1-7) to the pentapeptide Ang-(1-5) and that ACE inhibition markedly reduced the clearance of the peptide [30, 31]. The reduced metabolism of Ang-(1-7) likely contributes to the elevation in circulating levels of Ang-(1-7) following the chronic treatment with ACE inhibitors in experimental animals and in humans . Moreover, treatment with an ACE inhibitor was required to clearly demonstrate the accumulation of Ang-(1-7) derived from either Ang II or Ang I in isolated proximal tubules . These data suggest a pivotal role for ACE to regulate the balance of Ang II and Ang-(1-7), two peptides within the RAS that exhibit strikingly different actions from one another .
Chymases [EC 3. 4.21.39] comprise a family of serine peptidases that may generate Ang II by hydrolysis of the Phe8-His9 bond of Ang I and other peptide precursors [Ang-(1-12), Ang-(1-25)] (α-chymases) or metabolize Ang II at Tyr4-Ile5 to form Ang-(1-4) and Ang-(5-8) (β-chymases) [34–39]. Humans express α-chymase while rodents express primarily β-chymases, as well as other isoforms (mouse MCP-4 and rat MCP-5) that more closely resemble α-chymase in regard to the processing of Ang I to Ang II . The human and mouse enzymes may also play a role in the conversion of the endothelin precursor to the active peptide, as well as the activation of various inflammatory cytokines . Chymases (35 kDa) are synthesized and stored in an inactive proform within mast cells and neutrophils that are released with other proteases (cathepsin G, tryptases, and renin) upon degranulation following injury or inflammation . Although chymases are soluble enzymes, they associate with the cell membrane and may locate to the extracellular surface of tissues following release. The serine protease inhibitor chymostatin is typically used to demonstrate specificity; however, chymostatin inhibits other Ang II-generating enzymes (cathepsin G and elastase-2). Thus, chymostatin sensitivity for Ang II generation does not necessarily demonstrate the involvement of chymase and more selective approaches should be considered [42–45]. The extent that chymase or other peptidases participate in the formation of circulating or tissue Ang II through an ACE-independent pathway remains equivocal .
Neprilysin [EC 188.8.131.52; ~95 kDa] is a metalloendopeptidase that is predominantly anchored to the plasma membrane. The peptidase was initially characterized in brain to hydrolyze the opiate peptide enkephalin, hence the original terminology of the enzyme as “enkephalinase.” Neprilysin was subsequently found in a number of peripheral tissues with particularly high expression within the brush border on the apical region of the renal proximal tubules. Interest in the renal expression of neprilysin reflected the potential role of the peptidase to metabolize natriuretic peptides, and selective inhibitors alone or combined with an ACE inhibitor (“vasopeptidase inhibitor”) were developed as cardiovascular therapies to prolong the renal actions of these peptides [47–52]. Although the vasopeptidase inhibitor omapatrilat was clinically withdrawn regarding a greater incidence of angioedema that may reflect increased levels of bradykinin, a new generation of agents that combine a neprilysin inhibitor and an AT1R antagonist may be a promising therapeutic approach for the treatment of heart failure . One potential caveat to this approach would be that the neprilysin inhibitor component may reduce circulating levels of Ang-(1-7) and potentially attenuate the cardioprotective effects of the combined antagonist/inhibitor.
Vascular neprilysin is responsible for the extracellular conversion of Ang I to Ang-(1-7) in the circulation, particularly under conditions of chronic ACE inhibition (Figure 1) . Neprilysin hydrolyzes the Pro7-Phe8 bond of Ang I to form Ang-(1-7), as well as the Tyr4-Ile5 bond to generate Ang-(1-4) that reflects the enzyme’s preference for aromatic and hydrophobic residues. We further showed that renal neprilysin on the proximal tubules and the renal cortex readily converted both Ang I and Ang-(1-12) to Ang-(1-7), as well as that a neprilysin inhibitor attenuated the blood pressure-lowering effects of the ACE inhibitor lisinopril in the spontaneously hypertensive rat [33, 55, 56]. Apart from the conversion of Ang I to Ang-(1-7), neprilysin is capable of metabolizing a number of other peptides including adrenomedullin, Ang II [to Ang-(1-4)], endothelin, bradykinin, and the natriuretic peptides ANP and BNP.
6. Thimet oligopeptidase
Thimet oligopeptidase [EC 184.108.40.206, 80 kDa] is primarily a soluble metalloendopeptidase that resides within the cell. Similar to neprilysin, thimet oligopeptidase prefers aromatic and hydrophobic residues and cleaves multiple peptide substrates. In regard to the RAS, thimet oligopeptidase hydrolyzes Ang I exclusivity at the Pro-Phe bond to form Ang-(1-7) (Figure 1). We recently showed that both neprilysin and thimet oligopeptidase contributed to the processing of Ang I to Ang-(1-7) within isolated mitochondria . In the human proximal tubule HK-2 cell line, cytosolic thimet oligopeptidase was the sole activity responsible for the generation of Ang-(1-7) from exogenous Ang I . Moreover, thimet oligopeptidase activity in isolated nuclei processed Ang I exclusively to Ang-(1-7) and may be a potential candidate that contributes to the nuclear levels of Ang-(1-7) within the cell . The RAS was originally characterized as a classic endocrine or circulating system, but there is very compelling evidence for the intracellular expression of the RAS peptides, receptors, and synthetic components [7, 54, 58–60]. It is presently unclear the cellular mechanisms for the intracellular expression of Ang II or Ang-(1-7), although the intracellular peptidase thimet oligopeptidase may play a role in the cellular Ang-(1-7) axis.
7. Angiotensin-converting enzyme 2
ACE2 is a membrane-bound monocarboxypeptidase [EC 220.127.116.11; 120 kDa] that converts Ang II directly to Ang-(1-7) (Figure 1). ACE2 was initially characterized as a homolog to ACE and exhibits approximately ~40% homology with ACE [60–62]. ACE2 was initially reported to cleave Ang I not to Ang II, but to the nonapeptide Ang-(1-9) . Subsequent studies found that Ang II exhibits far better kinetic values for ACE2 that would argue that the endogenous substrate is Ang II, not Ang I . Among a number of peptide substrates (>100) that were screened for ACE2, Vickers et al. reported that only apelin 13 exhibited comparable kinetic values to that of Ang II . In the murine heart, Ang II was primarily converted to Ang-(1-7) by ACE2 and that in the presence of the ACE2 inhibitor MLN-4760 or in ACE2 null mice there was essentially no metabolism of Ang II in the heart . By contrast, under identical kinetic conditions, Ang I was primarily converted to Ang-(1-9) by carboxypeptidase A and not ACE2 in both the wild-type and ACE2 knockout mice.
In comparison to ACE, the circulating levels of ACE2 are typically quite low. Whether this reflects a reduced degree of shedding, lower vascular expression or both is not presently clear. Rice et al. reported that the molar concentration of ACE in human serum averaged 7 nM in over 500 subjects while ACE2 content was 200-fold lower (33 pM) and was detectable in <10% of the patient population . Circulating NEP content (290 pM) was also lower than ACE and evident in <30% of these patients . Serum and urinary ACE2 activities are elevated in diabetes, heart failure, and hypertension [68–70]. Circulating ACE2 activity increased approximately threefold in the diabetic hypertensive mRen2.Lewis rat; however, serum ACE activity also increased in the diabetic rats. As measured under identical kinetic conditions, serum ACE was far higher than ACE2 suggesting that the capacity to generate Ang II (or metabolize Ang-(1-7) and bradykinin) remains greater than the capability to form Ang-(1-7) from Ang II .
Similar to ACE, ACE2 has a potentially significant role in the RAS pathway as a single catalytic step metabolizes Ang II to attenuate the Ang II-AT1 receptor pathway, and generate Ang-(1-7) that would stimulate the Ang-(1-7)-AT7/Mas receptor axis (Figure 1) [71, 72]. Indeed, ACE2-deficient animals exhibit exaggerated responses to Ang II or under chronic conditions of an activated RAS [73–76]. In turn, overexpression of ACE2 or administration of the soluble form of the peptidase, which retains full enzymatic activity, attenuates the Ang II-dependent increase in blood pressure and indices of target organ injury [77–85]. In regard to the benefits of an activated ACE2 pathway, several compounds have been identified that may act as allosteric activators of ACE2 including xanthenone (XNT) and diminazene aceturate (DIZE) to promote a higher ratio of Ang-(1-7) to Ang II . Chronic treatment with DIZE ameliorated the extent of pulmonary hypertensin and fibrosis, renal tissue injury, and myocardial infarction consistent with enhanced levels of Ang-(1-7) and a reduction in Ang II [84, 87–90]. Interestingly, DIZE treatment was also associated with increased mRNA levels of ACE2 suggesting that DIZE may exhibit actions apart from the direct activation of the peptidase [87, 91]. However, it should be noted that the effects of DIZE on ACE2 activity or expression have not been confirmed by others. Haber et al.  found no effect of DIZE on soluble ACE2 activity or an influence on Ang II-dependent hypertension using similar doses of DIZE as previously reported. Velkosa et al.  also found no direct effect of various concentrations of DIZE on renal ACE2 activity and slightly increased renal ACE2 activity in the 5/6 nephrectomized rat following a 2-week administration. Of particular interest, the Velkosa study reported that DIZE normalized the marked increase in renal ACE activity suggesting that ACE may be a more relevant target than ACE2 . DIZE also failed to increase ACE2 activity or enhance the local vascular actions of Ang-(1-7) in the isolated pig coronary arteries .
Conceptually, the use of ACE2 as a therapeutic agent to chronically alter the balance of Ang II and Ang-(1-7) is challenging. ACE activity in the circulation and the vasculature surface is significant with a very high capacity to generate Ang II. This reflects not simply the abundance of ACE but the significant capability of angiotensinogen and renin to generate the ACE substrate Ang I. Moreover, reduced Ang II levels by exogenous ACE2 should stimulate the generation of Ang II that reflects the activation of negative feedback mechanisms on renin. Therefore, it is difficult to conceive sufficiently high levels of ACE2 that can be achieved to chronically reduce Ang II and increase Ang-(1-7) except with the possible addition of an ACE inhibitor. In this case, supplementation of ACE2 may degrade residual levels of Ang II and the circulating levels of Ang-(1-7) may be augmented, particularly as the Ang-(1-7)-degrading pathway in the circulation is attenuated by the ACE inhibitor.
8. Dipeptidyl peptidase 3
We demonstrated a role for ACE in the metabolism of Ang-(1-7), but there are other potential pathways that may regulate endogenous levels of the peptide . Marshall and colleagues reported that ACE and a second peptidase activity in the sheep cerebrospinal fluid degraded Ang-(1-7) [95–97]. Interestingly, the non-ACE-degrading activity accounted for a greater contribution of metabolism than ACE . Moreover, this activity was inversely correlated to CSF levels of Ang-(1-7) in control and betamethasone-exposed sheep, a model of fetal programming that exhibits elevated blood pressure and an attenuated baroreflex . Subsequent studies found the Ang-(1-7)-degrading activity in sheep brain and kidney cortex, as well as in the human proximal tubule HK-2 cell line [57, 98]. The enzyme activity exhibited unusual characteristics as Ang I and other peptides equal to or greater than 10 residues were not substrates for the peptidase [57, 98]. In addition, the peptidase was sensitive to both chelating agents such as o-phenanthroline and EDTA, and the sulfhydryl inhibitors APMA and PCMB [57, 98]. Additional studies identified the inhibitor JMV-390, originally developed to block the metalloendopeptidases neprilysin, thimet oligopeptidase, and neurolysin, that potently inhibited the Ang-(1-7)-degrading activity in the brain and kidney [IC50 <1 nM] [57, 98]. Conversely, specific inhibitors against these endopeptidases did not attenuate the Ang-(1-7)-degrading activity . Interestingly, the peptidase activity accounted for the sole degradative pathway in the cytosolic fraction and in the media of the HK-2 cells . Utilizing the HK-2 cells as the source of the Ang-(1-7)-degrading activity, we recently purified the peptidase from the cell cytosol by ion exchange and hydrophobic interaction chromatography and identified the enzyme as dipeptidyl peptidase 3 [EC 3.4. 14.4, DPP 3] .
DPP 3 belongs to a family of metalloaminopeptidases that sequentially cleave two residues from the N-terminus of peptides no more than eight residues in length and this likely explains our previous results that Ang I, apelin-13, and neurotensin were not substrates for the Ang-(1-7)-degrading activity in the CSF and brain . We obtained a human recombinant form of DPP 3 to show that the enzyme metabolized Ang-(1-7) in two cleavage steps . DPP 3 initially hydrolyzes Ang-(1-7) at the Arg2-Val3 bond to form Ang-(3-7) and the dipeptide Arg1-Asp2. Ang-(3-7) is then very rapidly cleaved at Tyr4-Ile5 to form Ang-(5-7) and Val3-Tyr4. The kinetic analysis of DPP 3 hydrolysis revealed a higher efficiency constant (kcat/km) for Ang-(3-7) than Ang-(1-7) (Figure 2) . The preferred hydrolysis of Ang-(3-7) by DPP 3 would account for our inability to demonstrate the accumulation of Ang-(3-7) following the initial metabolism of Ang-(1-7). In regard to an in vivo role for DPP 3 to modulate Ang-(1-7), human HK-2 cells were treated with varying doses of the JMV-390 inhibitor and we assessed both the endogenous content of Ang-(1-7) and the intracellular DPP-3/Ang-(1-7)-degrading activity in the cells. As shown in Figure 3, 20- and 200-nM JMV-390 reduced DPP3 activity by >30 and >80%, respectively, as compared to control suggesting that the inhibitor effectively penetrates the cells . The lower dose of JMV increased the cellular content Ang-(1-7) approximately twofold, although this did not reach statistical significance. The higher dose of JMV, however, significantly reduced the intracellular levels of the peptide . We interpret the latter results that the high dose may spill over to block other peptidases including thimet oligopeptidase that may be involved in the generation of Ang-(1-7) in the renal cells . Thus, the blockade of Ang-(1-7)-forming enzymes by the high-dose JMV may override any protective effects of DPP 3 inhibition. We are currently assessing alternative approaches to block DPP 3 within the HK-2 cells and assess both secreted and intracellular levels of Ang-(1-7), as well as Ang-(1-7)-dependent actions on these cells.
9. AGE-induced peptidase
Our recent studies assessed the potential role of Ang-(1-7) in the progression of epithelial-to-mesenchymal transition (EMT) in the renal epithelial NRK-52 cell line by either advanced glycation end products (AGEs) or the cytokine TGF-β . Ang-(1-7) essentially abolished the cellular indices for EMT in the NRK-52 cells likely through the inhibition of the noncanonical ERK 1/2-signaling pathway stimulated by AGE (100). Interestingly, AGE exposure reduced the intracellular levels of Ang-(1-7) but did not alter the cellular content of Ang II . Processing of Ang I to Ang-(1-7) by thimet oligopeptidase tended to be reduced by AGE; however, the intracellular metabolism of Ang-(1-7) to Ang-(1-4) was significantly increased by AGE exposure . These data suggest that AGE-induced EMT may reflect lower Ang-(1-7) tone in the renal epithelial cells that may be permissive for the progression of EMT and the increase in tissue fibrosis. Our preliminary data suggest that DPP 3 is not responsible for the AGE-induced metabolism of Ang-(1-7) in these cells and that another peptidase activity may participate in the cellular metabolism of the peptide. As shown in Figure 4A, the NRK-52 cytosolic fraction readily hydrolyzed the quenched Ang-(1-7) fluorescent substrate Abz1-Ang-(1-7)-Tyr7(NO2) to Abz-Ang-(1-4). By contrast, DPP 3 in the HK-2 renal cells did not cleave the Ang-(1-7) fluorescent peptide (Figure 4B). The failure of DPP 3 to cleave the fluorescent Ang-(1-7) substrate is consistent with the inability of DPP 3 to hydrolyze blocked N-terminal residues of peptides such as the Abz moiety on the Ang-(1-7) substrate. Moreover, hydrolysis of the N-terminally blocked Ang-(1-7) fluorescent substrate by the cytosolic fraction of the NRK-52 cells suggests the peptidase is likely an endopeptidase. Apart from the identification of the Ang-(1-7)-degrading activity in the NRK-52E cells, it remains to be determined whether intracellular levels of Ang-(1-7) influence the EMT process.
10. Characterization of peptidase pathways
In the review of the peptidases of the Ang-(1-7) axis, a brief discussion of the various biochemical approaches to characterize these enzymatic components is warranted. Ideally, utilization of the endogenous peptide substrates including Ang I, Ang II, and Ang-(1-7) should be assessed to identify the peptidase activities involved in the RAS . One advantage is that the contribution of various peptidases for a given peptide is directly comparable to determine the predominant pathway in a particular tissue or treatment condition. Peptidase activities derived by different synthetic substrates are not comparable unless standardized to the enzyme concentration. Moreover, the use of endogenous peptide substrates may reveal novel peptidase activities involved in angiotensin processing [102, 103]. Peptidase assays developed in our laboratory typically utilize 125I-radiolabled peptides coupled to high-performance liquid chromatography (HPLC)-based separation and automated in-line γ-detection. Advantages of this are that only microliter amounts of serum or microgram quantities of tissue are normally required that reflects detection sensitivity in the fmol range and the lack of detector interference or quenching .
More recent studies have incorporated mass spectroscopy (MS) detection of angiotensin metabolism in tissues, cells, and plasma, as well as the derivation of processing networks . Velez and colleagues applied HPLC-MS analysis of Ang I processing in rat glomeruli to reveal the predominant processing of Ang I to Ang-(1-7) catalyzed by neprilysin . Interestingly, the authors could not demonstrate an Ang I to Ang II pathway even following the blockade of the Ang-(1-7) pathway with a neprilysin inhibitor. Hildesbrand et al.  utilized a HPLC-tandem quadrupole system (HPLC-MS/MS) to reveal multiple metabolism pathways from Ang I to its N-terminal metabolites Ang-(5-10) and Ang-(4-10), as well as Ang II and Ang-(1-7) in immobilized proteins from human plasma. Suski et al.  reported that Ang I was primarily converted to Ang-(1-7) in vascular smooth muscle cells (VSMCs) as characterized by HPLC-MS/MS and confirms our earlier study that thimet oligopeptidase directly processed Ang I to Ang-(1-7) in rat VSMC . Grobe and colleagues have applied “in situ” MALDI to characterize both renal and cardiac metabolism of exogenous Ang II [107, 108]. Ang-(1-7) was the primary product from Ang II in the renal cortex while Ang III was the major metabolite in the medulla . In the heart, Ang III and Ang-(1-7) were products of Ang II metabolism catalyzed by APA and ACE2, respectively . These data confirm earlier HPLC-based studies on the contribution of ACE2 to Ang-(1-7) formation in the mouse and human heart [66, 109]. Although this approach cannot distinguish intracellular versus membrane or extracellular processing and requires relatively high-substrate concentrations, it is likely that these systems will develop the required sensitivity and resolution to detect peptides in situ, as well as characterize the extent of enzymatic processing.
Portions of this chapter are reproduced from the author’s recent publication . These studies were supported in part by grants from the National Institute of Health grants (HL-56973, HL-51952, HD084227, HD-047584, and HD-017644) and the American Heart Association (AHA-151521 and AHA-355741). An unrestricted grant from the Farley-Hudson Foundation (Jacksonville, NC), Groskert Heart Fund, and the Wake Forest Venture Fund is also acknowledged.